- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy B – Relapsed/Refractory Richter Transformation (RT)
This study looks at a new cell therapy called Tecartus for adults with a type of blood cancer called Richter Transformation that has come back or not responded to previous treatments. It aims to see how well it works and if it's safe.
For: Relapsed/refractory Richter Transformation (RT)France · Germany · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy C – Relapsed/Refractory Burkitt Lymphoma (BL)
This study is looking at a new treatment called Tecartus for adults in the UK with a specific type of blood cancer called Burkitt Lymphoma. It's for patients whose cancer has come back or hasn't responded to previous treatments. Researchers want to see how well Tecartus works.
For: Relapsed/Refractory Burkitt Lymphoma (BL)Netherlands · France · Austria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) – Substudy D - Relapsed/Refractory Hairy Cell Leukemia (HCL)
This study looks at a new cell therapy called Tecartus for adults with a rare blood cancer called hairy cell leukaemia. It aims to see how well it works and if it's safe for people whose cancer has come back or hasn't responded to previous treatments.
For: Relapsed/Refractory Hairy Cell LeukemiaNetherlands · Spain · Sweden - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) – Substudy A – Relapsed/Refractory Waldenstrom Macroglobulinemia
This study is testing a new cell therapy called Tecartus for adults in the UK with a rare blood cancer called Waldenstrom Macroglobulinemia. It's for people whose cancer has come back or hasn't responded to previous treatments. We want to see how well it works and if it's safe.
For: Relapsed/Refractory Waldenstrom Macroglobulinemia (WM)Netherlands · Spain · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A PHASE 2 MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN SUBJECTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA (INHL)
This study looks at a new type of cell therapy, Yescarta, for people with certain types of slow-growing non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. Researchers are checking how well it works and if it's safe over many years.
For: Follicular Lymphoma · Marginal Zone Lymphoma · Indolent Non-Hodgkin LymphomaFrance - AuthorisedTherapeutic confirmatory (Phase III)
Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR
This study looks at treating a children's cancer called neuroblastoma. We want to find the best way to treat children who have a lower chance of a severe form of the disease. This will help doctors choose the right treatment to give children the best chance of getting better.
For: low and intermediate risk neuroblastomaGermany - Active not recruitingPHASE2
A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
This study compares two ways to prepare adults with acute lymphoblastic leukaemia (ALL) for a stem cell transplant. It aims to find out if a slightly stronger treatment can better stop the cancer from coming back, without making the transplant recovery harder.
For: Acute Lymphoblastic LeukemiaUnited Kingdom